Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors.
P. A. Zucali
No relevant relationships to disclose
M. Simonelli
No relevant relationships to disclose
F. De Vincenzo
No relevant relationships to disclose
E. Lorenzi
No relevant relationships to disclose
L. Rimassa
No relevant relationships to disclose
L. Balzarini
No relevant relationships to disclose
V. Quagliuolo
No relevant relationships to disclose
A. Lambiase
Employment or Leadership Position - MolMed S.p.A.
C. Bordignon
Employment or Leadership Position - MolMed S.p.A.
A. Santoro
No relevant relationships to disclose